NUVB7:30 AMNuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Updatenuvationbio.com
NUVB8:00 AMNuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual CongressesPresentation / Abstractnuvationbio.com
NUVB4:05 PMNuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026nuvationbio.com
NUVB8:00 AMNuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Gliomanuvationbio.com